Zhu X - Search Results

1

Malignancies in systemic rheumatic diseases: A mini review.

Geng Z, Ye C, Zhu X. Geng Z, et al. Among authors: zhu x. Front Immunol. 2023 Feb 28;14:1095526. doi: 10.3389/fimmu.2023.1095526. eCollection 2023. Front Immunol. 2023. PMID: 36926334 Free PMC article. Review.

2

Leukemia cell-derived microvesicles induce T cell exhaustion via miRNA delivery.

Cui J, Li Q, Luo M, Zhong Z, Zhou S, Jiang L, Shen N, Geng Z, Cheng H, Meng L, Yi S, Sun H, Wu F, Zhu Z, Zou P, You Y, Guo AY, Zhu X. Cui J, et al. Among authors: zhu x, zhu z. Oncoimmunology. 2018 Mar 26;7(7):e1448330. doi: 10.1080/2162402X.2018.1448330. eCollection 2018. Oncoimmunology. 2018. PMID: 29900066 Free PMC article.

3

Anti-PD-1 therapy for clinical treatment of lymphoma: a single-arm meta-analysis.

Geng Z, Xiao Y, Zhu XJ, Ye C, Zhou JF. Geng Z, et al. Oncotarget. 2018 Oct 19;9(82):35343-35355. doi: 10.18632/oncotarget.26223. eCollection 2018 Oct 19. Oncotarget. 2018. PMID: 30450162 Free PMC article.

4

The Impact of Tyrosine Kinase Inhibitors on Chronic Myeloid Leukemia Stem Cells and the Implication in Discontinuation.

Jiang L, Wang H, Zhu X, Liu W, Zhou S, Geng Z, Xiao Y, Zou P, You Y, Li Q, Zhu X. Jiang L, et al. Among authors: zhu x. Stem Cells Dev. 2019 Nov 15;28(22):1480-1485. doi: 10.1089/scd.2019.0117. Epub 2019 Oct 22. Stem Cells Dev. 2019. PMID: 31530245

5

Tropism-facilitated delivery of CRISPR/Cas9 system with chimeric antigen receptor-extracellular vesicles against B-cell malignancies.

Xu Q, Zhang Z, Zhao L, Qin Y, Cai H, Geng Z, Zhu X, Zhang W, Zhang Y, Tan J, Wang J, Zhou J. Xu Q, et al. Among authors: zhu x. J Control Release. 2020 Oct 10;326:455-467. doi: 10.1016/j.jconrel.2020.07.033. Epub 2020 Jul 22. J Control Release. 2020. PMID: 32711027

6

Study on the Immune Escape Mechanism of Acute Myeloid Leukemia With DNMT3A Mutation.

Que Y, Li H, Lin L, Zhu X, Xiao M, Wang Y, Zhu L, Li D. Que Y, et al. Among authors: zhu x, zhu l. Front Immunol. 2021 May 20;12:653030. doi: 10.3389/fimmu.2021.653030. eCollection 2021. Front Immunol. 2021. PMID: 34093541 Free PMC article.

7

Chimeric Antigen Receptor-Modified T Cell Immunotherapy for Relapsed and Refractory Adult Burkitt Lymphoma.

Wu J, Cao Y, Zhang Q, Liu W, Zhou X, Ming X, Meng F, Zhang Y, Li C, Huang L, Wei J, Zheng M, Zhang S, Zhang T, Zhu X, Wang N, Wang J, Wang G, Zhou J, Liu B, Xiao Y. Wu J, et al. Among authors: zhu x. Front Immunol. 2022 May 20;13:879983. doi: 10.3389/fimmu.2022.879983. eCollection 2022. Front Immunol. 2022. PMID: 35669773 Free PMC article.

8

Analysis of causes for poor persistence of CAR-T cell therapy in vivo.

Kong Y, Tang L, You Y, Li Q, Zhu X. Kong Y, et al. Among authors: zhu x. Front Immunol. 2023 Jan 25;14:1063454. doi: 10.3389/fimmu.2023.1063454. eCollection 2023. Front Immunol. 2023. PMID: 36761742 Free PMC article. Review.

9

Case report: Sandwich therapy of CAR-T combined with ASCT: Sequential CAR-T cell therapy with ASCT after remission with CAR-T therapy caused long-term survival in a patient with relapsed/refractory Burkitt's lymphoma with TP53 mutations.

Zhang Q, Zhu X, Liu B, Zhang Y, Xiao Y. Zhang Q, et al. Among authors: zhu x. Front Immunol. 2023 Mar 17;14:1127868. doi: 10.3389/fimmu.2023.1127868. eCollection 2023. Front Immunol. 2023. PMID: 37006273 Free PMC article.

10

Demethylating therapy increases cytotoxicity of CD44v6 CAR-T cells against acute myeloid leukemia.

Tang L, Kong Y, Wang H, Zou P, Sun T, Liu Y, Zhang J, Jin N, Mao H, Zhu X, Wang J, Meng F, You Y. Tang L, et al. Among authors: zhu x. Front Immunol. 2023 Apr 27;14:1145441. doi: 10.3389/fimmu.2023.1145441. eCollection 2023. Front Immunol. 2023. PMID: 37180104 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

37,060 results

Search Page